Estimating severe acute respiratory coronavirus virus 2 (SARS-CoV-2) seroprevalence from residual clinical blood samples, January–March 2021

We describe severe acute respiratory coronavirus virus 2 (SARS-CoV-2) IgG seroprevalence and antigenemia among patients at a medical center in January–March 2021 using residual clinical blood samples. The overall seroprevalences were 17% by infection and 16% by vaccination. Spent or residual samples...

Descripción completa

Detalles Bibliográficos
Autores principales: Graciaa, Daniel S., Verkerke, Hans P., Guarner, Jeannette, Moldoveanu, Ana Maria, Cheedarla, Narayanaiah, Arthur, Connie M., Maier, Cheryl L., Neish, Andrew, Auld, Sara C., Campbell, Angie, Gandhi, Neel R., Roback, John D., Shah, N. Sarita
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cambridge University Press 2022
Materias:
Concise Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9726492/
https://www.ncbi.nlm.nih.gov/pubmed/36483398
http://dx.doi.org/10.1017/ash.2022.298
_version_ 1784844798714183680
author Graciaa, Daniel S.
Verkerke, Hans P.
Guarner, Jeannette
Moldoveanu, Ana Maria
Cheedarla, Narayanaiah
Arthur, Connie M.
Maier, Cheryl L.
Neish, Andrew
Auld, Sara C.
Campbell, Angie
Gandhi, Neel R.
Roback, John D.
Shah, N. Sarita
author_facet Graciaa, Daniel S.
Verkerke, Hans P.
Guarner, Jeannette
Moldoveanu, Ana Maria
Cheedarla, Narayanaiah
Arthur, Connie M.
Maier, Cheryl L.
Neish, Andrew
Auld, Sara C.
Campbell, Angie
Gandhi, Neel R.
Roback, John D.
Shah, N. Sarita
author_sort Graciaa, Daniel S.
collection PubMed
description We describe severe acute respiratory coronavirus virus 2 (SARS-CoV-2) IgG seroprevalence and antigenemia among patients at a medical center in January–March 2021 using residual clinical blood samples. The overall seroprevalences were 17% by infection and 16% by vaccination. Spent or residual samples are a feasible alternative for rapidly estimating seroprevalence or monitoring trends in infection and vaccination.
format Online
Article
Text
id pubmed-9726492
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Cambridge University Press
record_format MEDLINE/PubMed
spelling pubmed-97264922022-12-07 Estimating severe acute respiratory coronavirus virus 2 (SARS-CoV-2) seroprevalence from residual clinical blood samples, January–March 2021 Graciaa, Daniel S. Verkerke, Hans P. Guarner, Jeannette Moldoveanu, Ana Maria Cheedarla, Narayanaiah Arthur, Connie M. Maier, Cheryl L. Neish, Andrew Auld, Sara C. Campbell, Angie Gandhi, Neel R. Roback, John D. Shah, N. Sarita Antimicrob Steward Healthc Epidemiol Concise Communication We describe severe acute respiratory coronavirus virus 2 (SARS-CoV-2) IgG seroprevalence and antigenemia among patients at a medical center in January–March 2021 using residual clinical blood samples. The overall seroprevalences were 17% by infection and 16% by vaccination. Spent or residual samples are a feasible alternative for rapidly estimating seroprevalence or monitoring trends in infection and vaccination. Cambridge University Press 2022-09-22 /pmc/articles/PMC9726492/ /pubmed/36483398 http://dx.doi.org/10.1017/ash.2022.298 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by-nc-sa/4.0/This is an Open Access article, distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike licence (http://creativecommons.org/licenses/by-nc-sa/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the same Creative Commons licence is used to distribute the re-used or adapted article and the original article is properly cited. The written permission of Cambridge University Press must be obtained prior to any commercial use.
spellingShingle Concise Communication
Graciaa, Daniel S.
Verkerke, Hans P.
Guarner, Jeannette
Moldoveanu, Ana Maria
Cheedarla, Narayanaiah
Arthur, Connie M.
Maier, Cheryl L.
Neish, Andrew
Auld, Sara C.
Campbell, Angie
Gandhi, Neel R.
Roback, John D.
Shah, N. Sarita
Estimating severe acute respiratory coronavirus virus 2 (SARS-CoV-2) seroprevalence from residual clinical blood samples, January–March 2021
title Estimating severe acute respiratory coronavirus virus 2 (SARS-CoV-2) seroprevalence from residual clinical blood samples, January–March 2021
title_full Estimating severe acute respiratory coronavirus virus 2 (SARS-CoV-2) seroprevalence from residual clinical blood samples, January–March 2021
title_fullStr Estimating severe acute respiratory coronavirus virus 2 (SARS-CoV-2) seroprevalence from residual clinical blood samples, January–March 2021
title_full_unstemmed Estimating severe acute respiratory coronavirus virus 2 (SARS-CoV-2) seroprevalence from residual clinical blood samples, January–March 2021
title_short Estimating severe acute respiratory coronavirus virus 2 (SARS-CoV-2) seroprevalence from residual clinical blood samples, January–March 2021
title_sort estimating severe acute respiratory coronavirus virus 2 (sars-cov-2) seroprevalence from residual clinical blood samples, january–march 2021
topic Concise Communication
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9726492/
https://www.ncbi.nlm.nih.gov/pubmed/36483398
http://dx.doi.org/10.1017/ash.2022.298
work_keys_str_mv AT graciaadaniels estimatingsevereacuterespiratorycoronavirusvirus2sarscov2seroprevalencefromresidualclinicalbloodsamplesjanuarymarch2021
AT verkerkehansp estimatingsevereacuterespiratorycoronavirusvirus2sarscov2seroprevalencefromresidualclinicalbloodsamplesjanuarymarch2021
AT guarnerjeannette estimatingsevereacuterespiratorycoronavirusvirus2sarscov2seroprevalencefromresidualclinicalbloodsamplesjanuarymarch2021
AT moldoveanuanamaria estimatingsevereacuterespiratorycoronavirusvirus2sarscov2seroprevalencefromresidualclinicalbloodsamplesjanuarymarch2021
AT cheedarlanarayanaiah estimatingsevereacuterespiratorycoronavirusvirus2sarscov2seroprevalencefromresidualclinicalbloodsamplesjanuarymarch2021
AT arthurconniem estimatingsevereacuterespiratorycoronavirusvirus2sarscov2seroprevalencefromresidualclinicalbloodsamplesjanuarymarch2021
AT maiercheryll estimatingsevereacuterespiratorycoronavirusvirus2sarscov2seroprevalencefromresidualclinicalbloodsamplesjanuarymarch2021
AT neishandrew estimatingsevereacuterespiratorycoronavirusvirus2sarscov2seroprevalencefromresidualclinicalbloodsamplesjanuarymarch2021
AT auldsarac estimatingsevereacuterespiratorycoronavirusvirus2sarscov2seroprevalencefromresidualclinicalbloodsamplesjanuarymarch2021
AT campbellangie estimatingsevereacuterespiratorycoronavirusvirus2sarscov2seroprevalencefromresidualclinicalbloodsamplesjanuarymarch2021
AT gandhineelr estimatingsevereacuterespiratorycoronavirusvirus2sarscov2seroprevalencefromresidualclinicalbloodsamplesjanuarymarch2021
AT robackjohnd estimatingsevereacuterespiratorycoronavirusvirus2sarscov2seroprevalencefromresidualclinicalbloodsamplesjanuarymarch2021
AT shahnsarita estimatingsevereacuterespiratorycoronavirusvirus2sarscov2seroprevalencefromresidualclinicalbloodsamplesjanuarymarch2021

Ejemplares similares